This is the authors' abstract. We don't add key points for this paper.
Background: Homeobox A9 (HOXA9) has been implicated in acute myeloid leukemia and cancer breast but, little is known about HOXA9 expression in non- melanoma skin cancer (NMSC); basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). Objective: The aim of the current work was to study HOXA9 expression in NMSC by immunohistochemical method. Patients and Methods: This case-control study included a total of 45 cases with NMSC; 15 BCC and 30 SCC beside 45 age and sex-matched normal apparently healthy controls, selected from Dermatology, Andrology & Sexually transmitted diseases (STDs) Outpatient Clinic, Menoufia University Hospital, during the period December 2018 to June 2020. Clinical evaluation and histopathological evaluation confirmed the diagnosis of SCC and BCC. Results: Expression of HOXA9 in the overlying epidermis was positive in 83.3% of SCC cases with strong intensity in 68% and nucleocytoplasmic localization in 100%. HOXA9 was positive in 60% of BCC cases with mild intensity in 77.8% and nucleocytoplasmic localization in 100%. In control sections, HOXA9 was in all sections (100%) with strong intensity in 77.8%, and nucleocytoplasmic localization in all of them 100%. Regarding tumor islands; expression of HOXA9 was positive in 26 (86.7%) cases of SCC and was positive in 2 (13.3%) of BCC cases. There was significant higher HOXA9 H- score in control skin than NMSC (p < 0.001). Conclusions: It could be concluded that HOXA9 may be implicated in pathogenesis and may represent a target therapy for NMSC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Salama et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: